文献速递角膜与眼表疾病眼底病与葡萄膜炎

带状疱疹眼病复发:危险因素与长期临床结局

Herpes Zoster Ophthalmicus Recurrence: Risk Factors and Long-Term Clinical Outcomes.
PubMed 文献 · Am J Ophthalmol · 2024-06-22

该回顾性队列研究纳入2006至2016年单中心869例急性带状疱疹眼病患者,中位随访6.3年,200例(23.0%)出现至少1次复发,中位首次复发时间为3.5个月,最常见为葡萄膜炎(34.8%)。多因素分析显示免疫抑制、初诊眼压较高、角膜受累和葡萄膜炎是复发的预测因素,复发次数越多中度视力丧失比例越高。

要点

  • 869例急性带状疱疹眼病患者中,200例(23.0%)出现至少1次复发,中位首次复发时间3.5个月。
  • 复发的多因素预测因素包括免疫抑制(P = .026)、初诊眼压较高(P = .001)、角膜受累(P = .001)和葡萄膜炎(P < .001)。
  • 中度视力丧失(≤20/50)在0、1、2、3、4次及以上复发眼分别为15.5%、28.6%、31.4%、50.0%、57.4%。

核心结论

  • 带状疱疹眼病复发常见,复发次数越多视力丧失风险越高。
  • 这些发现提示需要密切监测潜在复发,尤其在停用局部糖皮质激素后及存在复发危险因素的个体中。

研究设计与样本

  • 回顾性队列研究,纳入2006至2016年单中心所有急性带状疱疹眼病患者,共869例,中位随访6.3年(四分位距3.7-8.9年)。

主要发现

  • 共观察到551次复发,200例(23.0%)出现至少1次复发,最常见为葡萄膜炎(34.8%),中位首次复发时间3.5个月。
  • 多因素分析中,复发的预测因素包括免疫抑制(P = .026)、初诊眼压较高(P = .001)、角膜受累(P = .001)和葡萄膜炎(P < .001)。
  • 437例在就诊第一个月内开始局部糖皮质激素治疗,其中184例(42.1%)观察到复发;停用局部糖皮质激素后,复发的中位时间为1.4个月(90%在7个月内)。
  • 中度视力丧失(≤20/50)在0、1、2、3、4次及以上复发的眼分别为15.5%、28.6%、31.4%、50.0%、57.4%。

临床怎么用

  • 作者认为需要密切监测潜在复发,尤其在停用局部糖皮质激素治疗后以及存在已识别复发危险因素的个体中。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the frequency of recurrences, risk factors, and long-term clinical outcomes in subjects with herpes zoster ophthalmicus (HZO). DESIGN: Retrospective cohort study. METHODS: All subjects with acute HZO seen at a single center from 2006 to 2016 were included in the study. The primary outcome measure was eye disease recurrence. The secondary outcome measure was moderate vision loss (≤20/50). RESULTS: A total of 869 patients with acute HZO were identified, with a median follow-up time of 6.3 years (interquartile range 3.7-8.9 years). In all, 551 recurrences were observed, and at least 1 recurrence was seen in 200 subjects (23.0%), with uveitis (34.8%) being the most common. The median time to first recurrence was 3.5 months. Predictors of disease recurrence included immunosuppression (P = .026), higher presenting intraocular pressure (P = .001), corneal involvement (P = .001), and uveitis (P < .001) on multivariate analysis. Topical steroids were initiated in the first month of presentation in 437 subjects, and recurrence was observed in 184 (42.1%) of these subjects. Following cessation of topical steroid treatment, recurrence occurred after a median of 1.4 months (90% within 7 months). Moderate vision loss (≤20/50) occurred in 15.5%, 28.6%, 31.4%, 50.0%, and 57.4% of eyes with 0, 1, 2, 3, and 4 or more recurrences. CONCLUSIONS: Recurrence of HZO eye disease is common, with an increased risk of vision loss with more recurrences. These findings indicate the need for close monitoring for potential recurrences, especially after cessation of topical steroid treatment, and in individuals with identified risk factors for recurrence.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Scott DAR, Liu K, Danesh-Meyer HV, et al. Herpes Zoster Ophthalmicus Recurrence: Risk Factors and Long-Term Clinical Outcomes. Am J Ophthalmol. 2024. PMID: 38909743. doi:10.1016/j.ajo.2024.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。